[Reevaluation of immunopotentiation therapy for cancer].
Various cancer immunotherapies are thought to be insufficient to suppress cancers by themselves. Thus, they are usually applied in cancer therapy as an immunopotentiator in combination with chemotherapy. However, chemotherapy itself seems to be hazardous for activated immune cells. On the other hand, immunotherapy after surgical treatment for cancer patients of stages I through III significantly reduced cancer deaths compared to historical control data for the same surgeon team. Some lymph node metastases are cured by immunotherapy after resection of the main tumors. The potential of immunocancer therapy and problems in the future development of new cancer therapies are discussed.
Toyoshima
K
K
Sumitomo Hospital.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D001500:BCG Vaccine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003110:Colonic Neoplasms / Q000276:immunology / Q000628:therapy; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D008297:Male; D015996:Survival Rate
D000276:Adjuvants, Immunologic; D001500:BCG Vaccine; D007155:Immunologic Factors